The Cytokines Market was valued at USD 71.2 billion in 2023. The industry is projected to grow from USD 77.4 billion in 2024 to USD 139.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.80% during the forecast period (2024 - 2032). The growing incidence of chronic illnesses and advancements in immunotherapy and biotechnology are the primary drivers that are propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
A significant part of the pathophysiology of cancer is played by the variety of cytokines that are generated in the cancer microenvironment. The growth and spread of cancer can be halted by cytokines that are secreted in reaction to infection, inflammation, and immunity. On the other hand, cytokines released from the host that stimulate proliferation, inhibit apoptosis, and aid in invasion and metastasis can also cause cancer cells to react. In order to overcome these obstacles, cytokines have been studied in a clinical setting in combination with checkpoint inhibitors, cancer-directed monoclonal antibodies, anticancer vaccines, chimeric antibody-cytokine fusion proteins (immunokines), newly engineered cytokine mutants (superkines), and anticancer vaccines to boost their antibody-dependent cellular cytotoxicity or maintain cellular responses and anticancer efficacy.
Factors like the expanded prevalence of disease, investigation, and funding in the field of disease treatment fuel market development. For example, according to the Globocan 2020, the quantity of new cancer growth cases revealed was 19,292,789. This count is supposed to ascend to 28,887,940 by 2040. In addition, the presence of competitors, item dispatches, joint efforts, pipeline resources, and research help market development. For example, in April 2022, Sonnet BioTherapeutics Holdings, Inc., a clinical-stage organization creating designated immunotherapeutic medications, distributed their information from preclinical investigations of the organization's exclusive Completely Human Albumin Binding candidates, Child 1010, Child 1210, and Child 1410, in a poster session at the American Association for Cancer Research (AACR) Yearly Gathering 2022.
Furthermore, developments in recombinant DNA technology make high-productivity and high-purity recombinant cytokines possible. Because of this breakthrough, cytokines are now more widely available for medicinal and research purposes, revolutionizing the production process. Biotechnology methods can engineer cytokines with enhanced stability, solubility, and pharmacokinetic characteristics. The use of engineered cytokines in clinical settings is prompted by their potential for improved therapeutic effectiveness and decreased immunogenicity.
Moreover, the use of cytokine-based immunotherapy is expected to rise, propelling the overall cytokine market's development. For instance, cytokine-based immunotherapy has an extraordinary commitment to the therapy of malignant growth. Subsequently, the utilization of cytokine-based immunotherapy is developing alongside the frequency of disease. The FDA has approved IL-2 and IFN-α for the therapy of disease. Regular endorsements and presentations of new items and medicines are expected to fuel the worldwide cytokine market's development. For instance, the Food and Medication Organization approved a new label update for Yescarta, a CAR T-cell treatment, in January 2022, which showed that utilizing steroids prophylactically works on the treatment of cytokine release syndrome. Thus, driving the Cytokines market revenue.
Based on Cytokine Type, the global Cytokines market segmentation includes Tumor Necrosis Factor- Tumor Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, and Other Cytokine Types. In 2023, the Tumor Necrosis Factor-TNF segment dominated the market. Tumor necrosis factor (TNF), a multipurpose cytokine, regulates a number of biological functions, such as coagulation, lipid metabolism, cell division, proliferation, and death. Tumor necrosis factor (TNF) alpha is among the first cytokines to be discovered. When acting locally, it mostly impacts vascular endothelial cells and leukocytes, inducing proinflammatory responses to pathogens (autocrine and paracrine). Among other functions, TNF cytokines aid in cell death, cachexia, proliferation, differentiation, lipid metabolism, and coagulation. Tasonermin, etanercept/Enbrel, golimumab, and infliximab are a few essential TNF-based medications. Two major producers of biological products that are engaged in the synthesis of TNF are Sigma Aldrich and R&D Systems.
The Interleukins-Il category is anticipated to be the fastest growing. The therapeutic uses of interleukins impact demand for them. For instance, IL-2 stimulates T-cell proliferation in cancer immunotherapy, whereas IL-6 inhibitors are used to treat inflammatory diseases like rheumatoid arthritis. Demand is impacted by how well interleukin-targeted treatments work. Clinical users are more likely to be in high demand for interleukins that have shown productivity and excellent safety profiles.
Based on therapeutic application, the global cytokine market segmentation includes cancer, asthma, airway inflammation, arthritis, and other therapeutic applications. In 2023, the cancer category generated the most income. Cytokine-based treatments can be utilized alone or related to different therapies like radiation, chemotherapy, or designated treatment. The targets of these blend treatments are to further develop therapy results and strengthen the immune reaction against malignant growth. Immunotherapy meds that discharge the brakes on the resistant framework enable it to recognize and combat cancer growth cells involving cytokines in their system of activity. Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1), for example, have some control over the amount and activity of cytokines in the cancer microenvironment.
The Cytokines’ asthma and airway inflammation segment market is anticipated to grow fastest during the forecast period. Eosinophilic asthma is a form of asthma linked to elevated Th2 cytokine production, defined by elevated eosinophil counts in the airways. Therapies that target IL-5, a crucial cytokine involved in eosinophil activation and survival, have effectively reduced asthma exacerbations and eosinophilic inflammation.
Figure 1: Global Cytokines Market by Therapeutic Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Cytokines market will dominate this market due to the higher incidence of cancer in the area, novel products and research and development (R&D) initiatives have been introduced. For example, according to the Globocan 2020 study, 2,556,022 Americans had cancer in 2020; by 2035, this number is predicted to increase to 3,316,283 Americans. Throughout the projected period, an upsurge in cancer cases is expected to fuel market expansion.
Additionally, at the American Association for Cancer Research (AACR) Annual Meeting in March 2022, Xenco presented preclinical data from XmAb Cytokine Programs. This clinical-stage biopharmaceutical company develops engineered antibodies and cytokines for the treatment of autoimmune diseases and cancer. As a result, more cytokine-related studies and research contribute to the market expansion in the area under study.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Global Cytokines Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Cytokines market accounts for the second-largest market share. Europe has a high emphasis on life sciences and a well-established research infrastructure. This encourages cytokine therapy innovation and advances the market. Further, the German Cytokines market held the largest market share, and the UK Cytokines market was the fastest-growing market in the European region.
The Asia-Pacific Cytokines Market is expected to grow at the fastest CAGR from 2024 to 2032 as a result of rising rates of chronic illnesses like cancer or rising cancer-related costs. Cytokine treatment, for example, aids the immune system in eliminating cancer cells or stopping their growth. The number of Indians with cancer is predicted to rise from 26.7 million in 2021 to 29.8 million in 2025, according to research on the "Burden of cancers in India" published by the Indian Council of Medical Research (ICMR). Moreover, China’s Cytokines market held the largest market share, and the Indian Cytokines market was the fastest-growing market in the Asia-Pacific region.
The industry's leading players will keep spending a lot of money on research and development to increase their product lines, which will propel the Cytokines market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Cytokines industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide Cytokines market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The Cytokines industry has recently provided some of the largest medical advantages. Major players in the Cytokines market, including GlaxoSmithKline PLC, Novartis AG, Sanofi SA, Amgen, Pfizer Inc., Biocon Limited, Abbvie Inc, AstraZeneca plc, Johnson and Johnson, and UCB S.A., and others, are making investments in R&D activities in an effort to boost market demand.
The clinical items organization Novartis AG is devoted to the examination, creation, production, and dissemination of drug things, both brand-name and conventional, as well as eye care things. It offers drugs to treat different ailments, including strong growths, immunological problems, contaminations, neurological problems, ophthalmology and respiratory illnesses, cardiovascular infections, dermatological issues, and hematologic sicknesses. Through its BioMedical Exploration division, Novartis completes research in various disease areas. Novartis expected to start a Stage III clinical preliminary in April 2020 to research Ilaris (canakinumab) in people experiencing Coronavirus pneumonia. An examination will look at the effectiveness of utilizing the interleukin (IL)- 1β blocker canakinumab to treat a specific sort of extreme immunological reaction.
In the area of biotechnology business, Amgen Inc. finds, makes, produces, and sells state-of-the-art human drugs to treat patients with hazardous ailments. Novel drugs are produced for the treatment of nephrology infections, irritation, oncology/hematology, cardiovascular ailments, and abnormalities of the bones. The business utilizes its understanding of human science and examination of ailment difficulties to make items that utilize state-of-the-art human hereditary qualities. Amgen, in particular, sells its items to US drug wholesale vendors. Furthermore, it utilizes associations with different organizations and direct-to-shopper channels to offer explicit things directly to clients. Amgen Inc., Guardant Wellbeing, and Qiagen NV declared in January 2020 that they would be cooperating to assist in sub-atomic testing for patients with non-small cell lung cancer.
Key Companies in the Cytokines market include
Cytokines Industry Developments
May 2022: The supplementary Biologics Permit Application (sBLA) for Dupixent (dupilumab) was acknowledged for importance review by the U.S. Food and Medication Organization (FDA) in the interest of Sanofi. Dupixent is utilized to treat individuals with prurigo nodularis, a persistent, irritating skin condition that results in extreme itching and skin lesions. September 30, 2022, is the FDA decision's target activity date. A totally human monoclonal neutralizer called dupixent doesn't suppress the resistant framework; rather, it impedes the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways.
July 2022: Worldwide innovator in biosimilar and generic medication producing, Sandoz, said that its Supplemental Biologics Permit Application (sBLA) for a high-focus formulation of 100 mg/mL (HCF) of its biosimilar Hyrimoz (adalimumab-Diaz) had been supported for assessment by the US Food and Drug Administration (FDA). The application covers rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis, as well as other conditions for which the reference medication Humira (adalimumab) is prescribed but is not covered by orphan exclusivity.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 71.2 Billion |
| Market Size 2024 | USD 77.4 Billion |
| Market Size 2032 | USD 139.8 Billion |
| Compound Annual Growth Rate (CAGR) | 8.80% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Cytokine Type, Therapeutic Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | GlaxoSmithkline PLC, Novartis AG, Sanofi SA, Amgen, Pfizer Inc., Biocon Limited, Abbvie Inc, AstraZeneca plc, Johnson and Johnson, and UCB S.A. |
| Key Market Opportunities | ·        Growing emphasis on immunotherapy in oncology and increasing gene editing technologies |
| Key Market Dynamics | ·        Growing incidence of chronic illnesses and rising advancement in immunotherapy and biotechnology |
Frequently Asked Questions (FAQ) :
The global Cytokines market size was valued at USD 71.2 Billion in 2023.
The global market is projected to grow at a CAGR of 8.80% during the forecast period 2024-2032.
North America had the largest share of the global market.
The key players in the market are GlaxoSmithKline PLC, Novartis AG, Sanofi SA, Amgen, Pfizer Inc., Biocon Limited, Abbvie Inc, AstraZeneca plc, Johnson and Johnson, and UCB S.A, among others.
The Tumor Necrosis Factor-TNF category dominated the market in 2023.
Cancer has the largest share of the global market.
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
